Patents Assigned to CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
-
Patent number: 11912645Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.Type: GrantFiled: April 27, 2018Date of Patent: February 27, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, UNIVERSITE PAUL SABATIER TOULOUSE III, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Nicolas Cenac, Justine Bertrand-Michel, Teresa Perez-Berezo, Thierry Durand, Jean-Marie Galano, Julien Pujo, Eric Oswald, Patricia Martin, Pauline Le Faouder, Alexandre Guy
-
Patent number: 11896649Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: September 27, 2022Date of Patent: February 13, 2024Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Publication number: 20230125698Abstract: The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the ?I7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the ?62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.Type: ApplicationFiled: March 25, 2021Publication date: April 27, 2023Applicants: UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE MARSEILLE, UNIVERSITE D'AIX-MARSEILLEInventors: Guy Serre, Géraldine Offer, Marianne Chabod, Mikael Pancarte, Jean Roudier, Nathalie Balandraud
-
Patent number: 11623003Abstract: Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.Type: GrantFiled: October 30, 2020Date of Patent: April 11, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Vincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
-
Patent number: 11484577Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.Type: GrantFiled: February 14, 2017Date of Patent: November 1, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Valet, Cedric Dray, Vincent Minville, Bernard Frances, Francois Labaste, Claire Vinel
-
Patent number: 11471538Abstract: The response of subjects suffering from cancer to MAPK inhibitors is dramatically impaired by secondary resistances and rapid relapse. So far, the molecular mechanisms driving these resistances are not completely understood. The inventors show that expression of 10 SLITRK6 (SLIT and NTRK-like family, member 6) is induced by a MAPK inhibitor (e.g. Vemurafenib) and the inhibition of its induction in presence of the MAPK inhibitor induces synthetic lethality. Thus, the only inhibition of SLITRK6 by an inhibitor of activity or expression should potentiate the antitumor effect of the MAPK inhibitors and avoid the emergence of a resistance to those compounds. Furthermore the specific expression of 15 SLITRK6 also paves the way of strategies based on depletion of the residual cancer cells by targeting them with anti-SLITRK6 antibodies capable of mediating ADCC or antibody-drug conjugates binding to SLITRK6.Type: GrantFiled: February 9, 2018Date of Patent: October 18, 2022Assignees: INSERM (INSTITUT NATIONAL DE LA SANTéET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Gilles Favre, Magdalena Pohorecka
-
Patent number: 11457900Abstract: The invention relates to a device for capture of cellular biomarkers circulating in an animal or human biological flow, characterised in that it is suitable for use in vivo and in that it comprises a means of filtration intended to retain the said cellular biomarkers, the said means of filtration comprising at least one through-aperture the dimensions of which are suitable for retaining the said cellular biomarkers and being integral with a support, the support taking the form of a hollow component.Type: GrantFiled: February 2, 2016Date of Patent: October 4, 2022Assignees: Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Universite Toulouse III—Paul SabatierInventors: Aline Cerf, Sylvain Sanson, Hélène Cayron, Alejandro Kayum Jimenez, Christophe Vieu, Bernard Malavaud
-
Patent number: 11376269Abstract: The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.Type: GrantFiled: May 5, 2017Date of Patent: July 5, 2022Assignees: INSERM, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Jean-Emmanuel Sarry, Christian Recher, Fabienne De Toni-Costes, Nesrine Aroua
-
Patent number: 11186634Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.Type: GrantFiled: July 28, 2017Date of Patent: November 30, 2021Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse, Institut Claudius RegaudInventors: Mary Poupot, Loïc Ysebaert, Marie Tosolini, Jean-Jacques Fournie, Pierre Brousset, Philippe Rochaix
-
Patent number: 11078277Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.Type: GrantFiled: February 1, 2017Date of Patent: August 3, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Thierry Levade, Bruno Segui, Florie Bertrand, Julia Rochotte, Anne Montfort, Nathalie Andrieu-Abadie, Celine Colacios Viatge, Nicolas Meyer
-
Patent number: 11061037Abstract: Disclosed herein is a method for classifying a patient at risk for heart failure, wherein the method comprises the steps of (i) measuring the concentration of IGFBP2 in a sample obtained from the patient and (ii) comparing the concentration of IGFBP2 measured in step (i) to a control value derived from the concentration of IGFBP2 in samples from patients who are at particular stages of heart failure and/or to a control value derived from the concentration of IGFBP2 in blood samples from healthy patients.Type: GrantFiled: January 12, 2018Date of Patent: July 13, 2021Assignees: INSERM (INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Philippe Rouet, Fatima Smih-Rouet, Franck Desmoulin, Michel Galinier
-
Patent number: 10918737Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.Type: GrantFiled: January 27, 2017Date of Patent: February 16, 2021Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de ToulouseInventors: Thierry Levade, Bruno Segui, Nicolas Meyer, Céline Colacios Viatgé, Nathalie Andrieu-Abadie, Florie Bertrand
-
Patent number: 10822415Abstract: The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.Type: GrantFiled: January 27, 2017Date of Patent: November 3, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), Université Toulouse III—Paul Sabatier, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Thierry Levade, Nicolas Meyer, Céline Colacios Viatgé, Caroline Imbert, Nathalie Andrieu-Abadie, Bruno Segui
-
Patent number: 10781293Abstract: The present invention relates to a process for preparing a biocompatible and biodegradable, porous three-dimensional polymer matrix, to the porous polymer matrix obtained by means of such a process, and also to the uses thereof, in particular as a support and for cell culture or in regenerative medicine, and in particular for cell therapy, in particular cardiac cell therapy.Type: GrantFiled: July 27, 2016Date of Patent: September 22, 2020Assignees: CENTRE HOSPITALIER UNIVERSITAIRE DE Toulouse, CENTRE NATIONAL DE LA RECHERCHE ScientifiqueInventors: Sophie Girod Fullana, Brigitte Sallerin, Raya Bushkalova, Caroline Ceccaldi
-
Patent number: 10760135Abstract: The present invention relates to methods for predicting pancreatic cancer treatment response.Type: GrantFiled: January 13, 2016Date of Patent: September 1, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Pierre Cordelier, Louis Buscail, Frédéric Lopez
-
Patent number: 10709776Abstract: The present invention relates to ex vivo method for producing outer membrane vesicles (OMVs) by expression or overexpression of the hemolysin F gene (hlyF) in gram-negative bacterium.Type: GrantFiled: April 7, 2015Date of Patent: July 14, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Eric Oswald, Patricia Martin, Kazunori Murase
-
Patent number: 10705076Abstract: A method for determining the quantity of anti-HLA antibodies of a liquid medium containing antibodies.Type: GrantFiled: February 15, 2013Date of Patent: July 7, 2020Assignees: UNIVERSITÉ PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSEInventors: Antoine Blancher, Nicolas Congy, Jean-Gerard Tiraby, Daniel Drocourt
-
Publication number: 20200081009Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumour in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumour cells obtained from said subject.Type: ApplicationFiled: July 15, 2019Publication date: March 12, 2020Applicants: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institute National de la Sante et de la Recherche Medicale (INSRM)Inventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud
-
Patent number: 10426818Abstract: The present invention relates to an APJ receptor agonist for use in the treatment or the prevention of diabetes.Type: GrantFiled: March 23, 2016Date of Patent: October 1, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paul Sabatier Toulouse, Centre Hospitalier Universitaire de ToulouseInventors: Philippe Valet, Isabelle Laurell, Laurent Cazals, Pierre Gourdy
-
Patent number: 10401365Abstract: The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.Type: GrantFiled: June 16, 2015Date of Patent: September 3, 2019Assignees: Universite Paul Sabatier (Toulouse III), Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Toulouse, Institut National de la Sante et de la Recherche MedicaleInventors: Catherine Muller, Victor Laurent, Adrien Guerard, Philippe Valet, Bernard Malavaud